more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: *https://www.gpo.gov/ fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.* 

*Docket:* For access to the docket to read background documents or the electronic and written/paper comments received, go to *https:// www.regulations.gov* and insert the docket number, found in brackets in the heading of this document, into the "Search" box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

## FOR FURTHER INFORMATION CONTACT:

Moon Hee V. Choi, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-9001, Fax: 301-847-8533, email: AADPAC@fda.hhs.gov, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). A notice in the Federal Register about last-minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check FDA's website at *https://www.fda.gov/* AdvisorvCommittees/default.htm and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before coming to the meeting.

#### SUPPLEMENTARY INFORMATION:

Agenda: The committees will discuss new drug application (NDA) 209774, for an immediate-release oral tablet formulation of oxycodone, which is intended to resist common methods of physical or chemical manipulation and to deter intravenous and intranasal abuse, submitted by SpecGx Inc., for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. The committees will also be asked to determine whether the Applicant adequately demonstrated that the abuse-deterrent properties of the proposed product are sufficient to include this information in the product label, and whether the product should be approved.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's website after the meeting. Background material is available at *https://www.fda.gov/ AdvisoryCommittees/Calendar/ default.htm.* Scroll down to the appropriate advisory committee meeting link.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committees. All electronic and written submissions submitted to the Docket (see ADDRESSES) on or before October 30, 2018, will be provided to the committees. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before October 22, 2018. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by October 23, 2018.

Persons attending FDA's advisory committee meetings are advised that FDA is not responsible for providing access to electrical outlets.

For press inquiries, please contact the Office of Media Affairs at *fdaoma*@ *fda.hhs.gov* or 301–796–4540.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact Moon Hee V. Choi (see FOR FURTHER INFORMATION CONTACT) at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our website at https://www.fda.gov/ AdvisoryCommittees/ AboutAdvisoryCommittees/ ucm111462.htm for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2). Dated: October 2, 2018. Leslie Kux, Associate Commissioner for Policy. [FR Doc. 2018–21810 Filed 10–5–18; 8:45 am] BILLING CODE 4164–01–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Health Resources and Services Administration

#### Charter Renewal for the Council on Graduate Medical Education

**AGENCY:** Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS). **ACTION:** Notice.

**SUMMARY:** HHS is hereby giving notice that the Council on Graduate Medical Education (COGME) has been rechartered. The date the renewed charter took effect is September 30, 2018.

FOR FURTHER INFORMATION CONTACT: Kennita R. Carter, MD, Designated Federal Official, COGME at 301–945– 3505 or email at *kcarter@hrsa.gov*. A copy of the current committee membership, charter, and reports can be obtained by accessing the website *http://www.hrsa.gov/advisory committees/bhpradvisory/COGME/ index.html*.

SUPPLEMENTARY INFORMATION: COGME provides advice and recommendations to the Secretary of the Department of Health and Human Services (Secretary), the Senate Committee on Health, Education, Labor and Pensions, and the U.S. House of Representatives Committee on Energy and Commerce on matters concerning the supply and distribution of physicians in the United States, physician workforce trends, training issues, financing policies and other matters of significance concerning graduate medical education, as specified by section 762 of the Public Health Service (PHS) Act, as amended. Additionally, COGME encourages entities providing graduate medical education to conduct activities to voluntarily achieve the recommendations of the Council; develops, publishes, and implements performance measures and longitudinal evaluations; and recommends appropriation levels for certain PHS Act Title VII programs. The charter renewal for COGME was approved on September 30, 2018, which will also stand as the filing date. Renewal of the COGME charter gives authorization for the Council to operate until September 30, 2020.

A copy of the COGME charter is available on the COGME website at: https://www.hrsa.gov/advisorycommittees/graduate-medical-edu/ index.html. A copy of the charter can also be obtained by accessing the FACA database that is maintained by the Committee Management Secretariat under the General Services Administration. The website for the FACA database is http:// www.facadatabase.gov/.

#### Amy P. McNulty,

Acting Director, Division of the Executive Secretariat.

[FR Doc. 2018–21864 Filed 10–5–18; 8:45 am] BILLING CODE 4165–15–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## **Performance Review Board Members**

Title 5, U.S.C. Section 4314(c)(4) of the Civil Service Reform Act of 1978, Public Law 95–454, requires that the appointment of Performance Review Board Members be published in the **Federal Register**.

The following persons may be named to serve on the Performance Review Boards or Panels, which oversee the evaluation of performance appraisals of Senior Executive Service members of the Department of Health and Human Services.

Employee	Employee
last name	first name
Barry	Daniel
Brady	William
Brown	Mark
Coquis	Roberto
Fantinato	Jessica
Fischmann	Elizabeth
Gentile	John
Goldhaber	Ben
Hargan	Eric
Haseltine	Amy
Kretschmaier	Michon
Lewis	Lisa
McDaniel	Eileen
Novy	Steve
Rowell	Scott
Sample	Allen
Skeadas	Christos
Tobias	Constance

Dated: October 1, 2018.

Charles H. McEnerney III,

Director, Executive and Scientific Resources Division.

[FR Doc. 2018–21855 Filed 10–5–18; 8:45 am] BILLING CODE 4151–17–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Meeting of the National Clinical Care Commission

**AGENCY:** Office of Disease Prevention and Health Promotion, Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services.

# ACTION: Notice.

SUMMARY: The National Clinical Care Commission (the Commission) will conduct its inaugural meeting on October 31, 2018. The Commission will evaluate and make recommendations to the U.S. Department of Health and Human Services (HHS) Secretary and Congress regarding improvements to the coordination and leveraging of federal programs related to awareness and clinical care for complex metabolic or autoimmune diseases that result from issues related to insulin that represent a significant disease burden in the United States, which may include complications due to such diseases. DATES: The meeting will take place on October 31, 2018, from 8:00 a.m. to approximately 5:00 p.m. Eastern Time (ĒŤ).

ADDRESSES: National Institutes of Health, Building 35, John Edward Porter Neuroscience Research Center [PNRC II], 35 Convent Drive, Bethesda, MD 20892. The meeting will also be held online via webcast. To register to attend the meeting, please visit the registration website at https:// events.kauffmaninc.com/events/

ncccmeetingone/.

FOR FURTHER INFORMATION CONTACT: Clydette Powell, Designated Federal Official, National Clinical Care Commission, U.S. Department of Health and Human Services, Office of the Assistant Secretary for Health, Office of Disease Prevention and Health Promotion, 1101 Wootton Parkway, Suite LL–100, Rockville, MD 20852. Email: *OHQ@hhs.gov.* Additional information may be obtained at *https:// health.gov/hcq/national-clinical-carecommission.asp.* 

**SUPPLEMENTARY INFORMATION:** The National Clinical Care Commission Act (Pub. L. 115–80) requires the HHS Secretary to establish the National Clinical Care Commission. The Commission will consist of representatives of specific federal agencies and non-federal individuals and entities who represent diverse disciplines and views. The Commission will evaluate and make recommendations to the HHS Secretary and Congress regarding improvements to the coordination and leveraging of federal programs related to awareness and clinical care for complex metabolic or autoimmune diseases that result from issues related to insulin that represent a significant disease burden in the United States, which may include complications due to such diseases.

This inaugural meeting of the Commission will consist of swearing-in non-federal Commission members, an overview of various federal interagency efforts surrounding diabetes programs, the establishment of the Commission subcommittee structure, and setting future agenda topics. The names and biographies of the Commission members and final meeting agenda will be available prior to the meeting at https:// health.gov/hcq/national-clinical-carecommission.asp.

Public Participation at Meeting: The Commission invites public comment on issues related to the Commission's charge either in-person at the meeting or in writing. In-person attendees who plan to provide oral comments at the Commission meeting during a designated time must submit their comments to OHQ@hhs.gov on or before October 24, 2018 and must check-in onsite. To accommodate as many individuals as possible, the time for each comment will be limited to three minutes. If more requests are received than can be accommodated, speakers will be randomly selected. The nature of the comments will not be considered in making this selection. Written comments are welcome throughout the entire development process of the Commission and may be emailed to OHQ@hhs.gov, or by mail to the following address: Public Commentary, National Clinical Care Commission, 1101 Wootton Parkway, Suite LL-100, Rockville, MD 20852. Written comments should not exceed three pages in length.

To attend the Commission meeting, individuals must pre-register at the registration website at https:// events.kauffmaninc.com/events/ *ncccmeetingone*/. In-person and live videocast attendance options are available. In-person attendance at the meeting is limited to space available. Inperson registrations will be accepted until maximum capacity is reached and must be completed by October 25, 2018. On the day of the meeting, seating will be provided first to persons who have pre-registered. Those who have not preregistered will be accommodate on a first come, first served basis if additional seats are still available 10 minutes before the meeting start. Individuals who need special assistance, such as sign language